Latest market price
20.62
+0.71+3.57%
ENOVQT43Enovis Corporation·NYSE
20.62+3.57%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E—EPS (ttm)-19.40Insider Own9.17%Shs Outstand57.67MPerf Week-2.55%
Market Cap1.19BForward P/E5.82EPS next Y3.54Insider Trans0.52%Shs Float56.24MPerf Month16.04%
Enterprise Value2.52BPEG—EPS next Q0.77Short Float20.81%Perf Quarter-33.18%
Income-1.10BP/S0.52EPS this Y13.40%Short Ratio7.90Perf Half Y-11.65%
Sales2.30BP/B0.80EPS next Y-2.31%ROA-29.25%Short Interest11.70MPerf YTD-22.60%
Book/sh25.65P/C91.48EPS next 5Y8.40%ROE-68.17%52W High32.41 -36.38%Perf Year-32.81%
Cash/sh0.23P/FCF18.88EPS past 3/5Y—ROIC2.95%52W Low16.70 23.47%Perf 3Y-52.78%
Dividend Est.—EV/EBITDA—Sales past 3/5Y12.88% 14.93%Gross Margin57.43%Volatility6.53% 4.99%Perf 5Y-76.67%
Dividend TTM—EV/Sales1.10EPS Y/Y TTM—Oper. Margin4.14%ATR (14)1.13Perf 10Y-60.09%
Dividend Ex-Date—Quick Ratio1.00Sales Y/Y TTM4.89%Profit Margin-47.97%RSI (14)52.20Recom2.20
Dividend Gr. 3/5Y—Current Ratio1.98EPS Q/Q13.92%SMA203.70%Beta1.07Target Price36.33
Payout0.00%Debt/Eq0.91Sales Q/Q3.19%SMA503.63%Rel Volume1.57Prev Close19.91
Employees7,802LT Debt/Eq0.88EarningsNov 05SMA200-10.56%Avg Volume1.59MPrice20.62
IPO DateMay 08, 2008Option/ShortYes / YesEPS/Sales Surpr.6.27% 0.16%Net Debt/EBITDA—Volume2,493,190Change3.57%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-12-26ReiteratedNeedhamBuy$52 → $34
Oct-05-26ReiteratedUBSBuy$51 → $44
Sep-01-26ReiteratedBMO Capital$30 → $27
Sep-01-26ReiteratedBTIGBuy$41 → $36
Aug-17-26ReiteratedCanaccord GenuityBuy$50 → $45
Aug-07-26ReiteratedBMO Capital$29 → $30
Jul-28-26ReiteratedUBSBuy$50 → $51
Jul-08-26InitiatedBMO CapitalOutperform$29
Jul-06-26ReiteratedEvercore ISI GroupOutperform$36 → $32
May-08-26ReiteratedEvercore ISI GroupOutperform$40 → $36
Latest News· Times ET
Oct-24-26
Oct-22-26
Oct-15-26
Oct-12-26
Oct-08-26
Oct-06-26
Sep-28-26
Sep-22-26
Sep-17-26
Sep-16-26
Sep-14-26
Sep-04-26
Sep-03-26
Company

Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,2972,2482,1081,707—————
Cost of Goods Sold Incl. D&A978903927716—————
Gross Profit1,3191,3451,181991—————
Selling, General and Administrative Excl. Other1,0541,070939830—————
Research and Development1251209175—————
Other Operating Expense45174926151—————
Operating Income94-19-776-66—————
Interest Expense56355720—————
Unusual Expense
—————————
Non-Operating Income (Expense)-1,107-1,1061018—————
Net Income Before Taxes-1,069-1,159-823-67—————
Income Taxes31224-13—————
Consolidated Net Income-1,102-1,184-825-33—————
Net Income From Continuing Operations-1,099-1,182-827-54—————
Net Income-1,102-1,184-825-33—————
EPS (Recurring)-19.40-20.86-14.93-0.61—————
EPS (Basic, Before Extraordinaries)-19.40-20.86-14.93-0.61—————
EPS (Diluted)-19.40-20.86-14.93-0.61—————
EBITDA-717-830-481170—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio0.520.681.141.77—————
Gross Margin57.4259.8356.0258.06—————
Operating Margin4.09-0.85-36.81-3.87—————
Net Margin-47.98-52.67-39.14-1.93—————
Shares Outstanding58575554—————
Market Capitalization1,1961,5182,4133,025—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$35.70$30.54$25.38$20.21$15.05● Close Price0.00K112.40K224.80K337.20K449.60KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Engert OliverChief Administrative OfficerSep 04 '26Buy18.802,66050,00863,898Sep 08
McDonald DamienChief Executive OfficerSep 04 '26Buy19.1513,035249,620247,077Sep 04
Engert OliverChief Administrative OfficerSep 03 '26Buy19.465,140100,02461,238Sep 04
Engert OliverChief Administrative OfficerSep 02 '26Buy20.322,45849,94756,098Sep 04
Engert OliverChief Administrative OfficerJun 15 '26Buy20.921,00020,92053,640Jun 16
Engert OliverChief Administrative OfficerJun 11 '26Buy21.621,20025,94851,840Jun 15
Engert OliverChief Administrative OfficerJun 10 '26Buy23.001,00023,00050,640Jun 11
Engert OliverChief Administrative OfficerJun 01 '26Buy22.221,00022,22049,640Jun 03
Engert OliverChief Administrative OfficerMar 13 '26Buy23.741,00023,74048,640Mar 16
Engert OliverChief Administrative OfficerMar 10 '26Buy23.931,00023,93047,640Mar 12
Engert OliverChief Administrative OfficerMar 09 '26Buy23.391,00023,39046,640Mar 10
Engert OliverChief Administrative OfficerMar 06 '26Buy24.4175018,31045,640Mar 10
Engert OliverChief Administrative OfficerMar 04 '26Buy25.102506,27544,890Mar 05
Engert OliverChief Administrative OfficerMar 03 '26Buy24.771,00024,77044,640Mar 05
Engert OliverChief Administrative OfficerFeb 27 '26Buy25.501,00025,50043,640Mar 03
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.